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ABSTRACT 
Until recently, Chloroquine was the mainstay for malaria chemotherapy in Africa because it is cheap, safe 
and practicable for out-patient use. Resistance to this drug has however over the past decade, presented a 
major public health problem with therapeutic and prophylactic implications.  As a response to the emergence 
of resistance to the commonly used antimalarial drugs, the World Health Organisation (WHO) now 
recommends the use of artemisinin-based combination therapies (ACTs). We assessed the therapeutic 
efficacy of oral Artesunate-Amodiaquine hydrochloride combination therapy in the treatment of 
uncomplicated falciparum malaria in a rural fishing community in Sierra Leone. One hundred and fourteen 
(114) participants aged 0 – 5 years attending the Outpatient Department of Gbondapi Health Centre were 
screened for recruitment into the study of which 70 fulfilled the inclusion criteria. Artesunate-Amodiaquine 
hydrochloride combined drug which passed the general counterfeit test of the Ministry of Health and 
Sanitation was used in the study. Adequate Clinical and parasitological Response (ACPR) was observed in 
97% of the study population. Mean parasite clearance time in the participants with ACPR was found to be 24 
hours (range 24 –72 hours). All 3% of the treatment failures were observed to be Early Treatment Failures 
(ETF). Results from the study indicate that Artesunate-Amodiaquine hydrochloride combination therapy is an 
effective antimalarial drug in a high transmission zone like Sierra Leone, and in the event that the drug is not 
effective, the results will be evident within one day of commencement of treatment.  
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INTRODUCTION 
Malaria has been reported as the leading cause 
of death in most countries in sub-saharan Africa 
with children below five years bearing the most 
morbidity and mortality (Taylor et al., 1993). Until 
recently, chloroquine was the mainstay for 
malaria chemotherapy in Africa because it is 
cheap, safe and practicable for outpatient use 
(Sahr et al., 2004). Resistance to this drug and 
other antimalarial drugs has however over the 
past decade, presented a major Public Health 
problem with therapeutic and prophylactic 
implications (Sahr et al., 2001). There is 
accumulating evidence that diminished sensitivity 
of the Plasmodium parasites to these commonly 
used antimalarial drugs is spreading (Simon et al., 
1988; Oduola et al., 1989; Brasseur et al., 1992; 
Sowunmi and Oduola, 1997), and hence, 
strategies to prevent further spread and the 
availability of treatment options are urgently 
required. One such drug introduced for the 
treatment of multidrug-resistant falciparum 
malaria is artemisinin.  
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The susceptibility of Plasmodium falciparum to 
artemisinin has been well established (Elhassan 
et al., 1993; Von Seidlein et al., 2000), and its 
effectiveness in the treatment of falciparum 
malaria in Africa has also been well documented 
(White et al., 1992; Elhassan et al., 1993; Taylor 
et al., 1993; Sowunmi and Oduola 1998). 
 
Recent reports suggest an emergence of 
decreased sensitivity of the malaria parasite to 
artemisinin when used as monotherapy (Gay et 
al., 1994; Sahr et al., 2001). As a response to the 
emergence of such resistance, the World Health 
Organisation (WHO) now recommends the use of 
artemisinin-based combination therapies (ACTs) 
(WHO, 2006). Three such combinations 
commonly use in Sierra Leone are artesunate-
amodiaquine, artesunate-lumefantrine and 
artesunate-sulfadoxime-pyrimethamine 
combinations. There is no available data on the 
efficacy of these combination drugs in Sierra 
Leone, but limited data collected by the Ministry of 
Health and Sanitation suggests that failed 
treatment to these newly introduced artemesinin-
combinations is very rare (unpublished data). The 
objective of the present study is therefore to 
assess the therapeutic efficacy of oral Artesunate-
Amodiaquine Hydrohloride combination therapy in 
the treatment of uncomplicated falciparum malaria 
in a rural farming and fishing community in Sierra 
Leone. 
 
PARTICIPANTS AND METHODS 
Study Site and Population 
The study was conducted in Gbondapi village 
which is an established fishing settlement located 
in the Mao Sakrim Chiefdom, Pujehun District in 
the Southern Province of Sierra Leone.  The 
village is divided into 3 communities – Gbondapi, 
Mani and Sumbuya and is bordered on the east 
by the Yakemo Kpukumu Krim and Kpaka 
Chiefdoms, on the South by the Atlantic Ocean, 
northwest by Kwamebai Chiefdom and on the 
North by Panga Krim Chiefdom. Because of the 
very close proximity between Mani and Sumbuya, 
and the relatively few participants registered from 
Sumbuya, all the participants from this community 
were registered under Mani. Majority of the 5,000 
residents speak mende, creole and a few speak 
English.  There is a government assisted health 
centre in the village that is supervised by a 
Community Health Officer, with referrals often 
made to the district Hospital in Pujehun town that 
is 80 kilometers away. Malaria transmission in this 
area is high and peaks during the rainy season.  
The village depends on a few hand-pump wells 
and unprotected streams for domestic water use, 
and poorly built pit-latrines for adults while 
children defecate indiscriminately between 
houses. 
 
Sample Collection and Examination 
Data was collected from the Primary Health 
Centre. The Health Centre serves all age groups 
in the three communities and subjects enrolled for 
the study were children below 5 years attending 
the Gbondapi Health Centre. The WHO Protocol 
(WHO 2003) for the recruitment of participants in 
therapeutic efficacy trials in high transmission 
zones was applied. The inclusion criteria were:  
Children below 5 years, temperature ≥ 37.5
o
C, 
mono-infection with Plasmodium falciparum, 
parasitemia ≥ 1000 parasites/µl of blood and 
Informed consent from accompanying parents. 
Participants with severe or complicated malaria 
according to the WHO classification (WHO 1996) 
were excluded from the study and treated with 
parenteral quinine dihydrochloride. Arteunate-
Amodiaquine hydrochloride combined drug which 
passed the general counterfeit test of the Ministry 
of Health and Sanitation was used in the study. 
Each tablet of Artesunate contained 50mg 
Artesunate and each tablet of Amodiaquine 
hydrochloride contained 150mg Amodiaquine. 
The test drug was administered orally over a 
three day period under the direct supervision of 
Community Health Officer (CHO) in the following 
dosages as directed by the manufacturers (Guilin 
Pharmaceutical Co. Ltd. China): 
 
Adults: 2 tablets of Artesunate with 2 
tablets Amodiaquine 
hydrochloride 12 hourly for three 
days 
7 – 13 years: 1 tablet Artesunate with 1 tablet 
Amodiaquine hydrochloride 12 
hourly for three days. 
1 – 6 years: Half tablet Artesunate with half 
tablet Amodiaquine hydrochloride 
tablet 12 hourly for three days.  
 
All participants were followed-up on days 1, 
2,3,7,14,21 and 28 during which the child’s 
general condition was assessed and blood smear 
prepared for the assessment and demonstration 
of malaria parasites.  
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Axillary temperature of all each participant was 
also recorded on each of the follow-up days. The 
response to the test drug was recorded according 
to the recommendation of the WHO (WHO 1996): 
Adequate clinical and parasitological response 
(ACPR), Early Treatment Failure (ETF) and Late 
Treatment Failure (LTF). Briefly, ACPR was 
defined as the absence of parasitemia on day 14 
irrespective of axillary temperature or axillary 
temperature less than 37.5
o
C irrespective of 
parasitemia, without previously meeting any of the 
criteria of ETF. Therapeutic response was 
classified as ETF if the subject developed one of 
the following conditions during the first three days 
of follow-up. 
 
a) Axillary temperature ≥ 37.5
O
C  on day 2 
with parasitemia greater than that on day 
0 or 
b) Axillary temperature ≥ 37.5
O
C on day 3 in 
the presence of parasitemia  
or  
c) Parasitemia on day 3 ≥ 25% of count on 
day 0. 
 
Therapeutic response was classified as LTF if a 
subject had axillary temperature ≥ 37.5
O
C in the 
presence of parasitemia on any day from day 4 to 
day 14 without previously meeting any of the 
criteria of ETF. All subjects with ETF and LTF 
were put on quinine sulphate 10mg/kg 8 hourly for 
at least five days. 
 
Ethical Clearance 
Ethical clearance for the study was obtained from 
the Research and Ethics Committee of the 
Ministry of Health and Sanitation.  
 
RESULTS 
A total of 114 participants were screened for 
enrollment into the study, of which 70 fulfilled the 
enrolment criteria. Laboratory data of the 
participants enrolled into the study is summarized 
in Table I. The mean age of the participants was 
17.2 months and the mean parasite count on the 
day of enrolment (day 0) was 1264 parasites/µl of 
blood. The temperature of the participants on the 
day of enrolment ranged from 37.8-39.2ºC with a 
mean of 38.1ºC.   
 
TABLE 1: Laboratory data of participants enrolled in Artesunate-Amodiaquine Hydrochloride 
Combined Therapy efficacy study in Gbondapi and Mani 
 
 Variable 
No of subjects screened 114 
No of subjects recruited 70 













37.8 – 39.2 






1006 – 2430 
 
The therapeutic responses of the 70 participants 
enrolled in the study are summarized in Table 2. 
All 70 participants completed the 28 day follow 
up. The mean fever clearance time with the test 
drug was one day (range 24-72 hours), and the 
mean  
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Table 2: Summary of the Therapeutic Response of Participants enrolled in Artesunate-Amodiaquine 
hydrochloride Combined Therapy Study 
 
 Variable 
No enrolled in study 70 
No completed in study  70 




24 – 72 
Parasite clearance time(hours) of children with 





24 – 72 
No (%) of subjects with Adequate Clinical Response 
(ACPR) 
68 (97) 




Adequate Clinical Response (ACPR) to the drug 
was observed in 97% of the participants with only 
3% showing treatment failures. According to the 
WHO classification of treatment failures (WHO 
2003), all 3% treatment failures were observed to 
be Early Treatment Failures (ETF). 
 
DISCUSSION 
Because resistance to the commonly used 
antimalarial drugs is a global problem, 
Artemisinin–based combination therapies (ACTS) 
are now the first-line therapies in most malaria-
endemic countries.  The commonly used 
artemesinin-based combination therapies in the 
treatment of uncomplicated falciparum malaria 
are Artemether-mefloquine and Artemether-
lumefantrine (WHO, 2006). Another available 
Artemesinin combination is the Artesunate-
Amodiaquine, which is recommended by the 
Ministry of Health and Sanitation of Sierra Leone 
as the first-line drug in the treatment of 
uncomplicated falciparum malaria.  
 
The results of this study suggest that Artesunate-
Amodiaquine combined therapy is highly 
efficacious in the treatment of falciparum malaria 
in Sierra Leone as evidenced by the 97% clinical 
response obtained. Recent clinical and molecular 
studies suggest the emergence of ACT-resistant 
Plasmodium falciparum infections in the 
Cambodia-Thailand border area, were the 
standard ACT is Artesunate-mefloquine 
combination (Wongsrichanalia et al., 2000). It was 
suggested that treatment failures observed in that 
study might be due to the high-level mefloquine 
resistance, as mefloquine was used as 
monotherapy in the treatment of falciparum 
malaria long before the introduction of ACT. 
 
Sahr et al. (2001) have reported 4 cases of 
apparent drug failure in Sierra Leone with the use 
of Artesunate as monotherapy. The four cases 
described indicate that although Artesunate is a 
safe alternative drug to Chloroquine, resistance to 
it is slowly emerging on the African continent. 
Using the criteria of the World Health 
Organisation in the classification of treatment 
failures, no late treatment failures (LTF) were 
observed within our study population.  This 
indicates that in the event that Artesunate-
Amodiaquine combined therapy is not effective, 
the result will be known within a day of 
commencement of therapy. The Artemisinins are 
characterized by a rapid reduction of parasitemia 
which begins almost immediately on 
commencement of treatment with complete 
clearance usually occurring within 48 hours. 
Several reports suggest that radical cure can be 
achieved with the Artemisinins when they are 
combined with other antimalarial drugs 
(Looareesuwan et al., 1992; Nosten et al., 1994; 
Prince et al., 1995; Von Seidlein et al., 2000). 
 
Results of a survey conducted in the capital 
Freetown among pharmacies on the sale of 
antimalarial drugs revealed that Artesunate ranks 
high in the list with most of the drug sold without 
prescriptions (Sahr et al., 1999). 
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It is thought that if the unregulated use of 
Artesunate or its combined antimalarial drugs 
continues, there is a high tendency of enhancing 
the development of resistance to the drug among 
the Sierra Leonean population. It is therefore 
recommended that measures are put in place by 
the Ministry of Health and Sanitation to restrict the 
distribution and sale of Artesunate-combination 
drugs so as to reduce the tendency of the 
development of resistance to the drug. 
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